Yoon Jong Park

Mr. Yoon Jong Park

Kangwon National University, Chuncheon 24341, South Korea
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
YPYoon Jong Park
Yoon Jong Park
HNHan-Heom Na
Han-Heom Na
IKIn-Seo Kwon
In-Seo Kwon
YHYu-Na Hwang
Yu-Na Hwang
HPHye-Jin Park
Hye-Jin Park
KKKeun-Cheol Kim
Keun-Cheol Kim
Extracts of phytocannabinoids from Cannabis sativa have been studied for therapeutic purposes. Although nonpsychoactive CBD has been studied as a promising anticancer drug because it induces apoptosis in many cancer cells, it is also known to induce several physiological changes. In this study, we clarify the functional role it plays in the morphological characteristics of intracellular vesicle formation as well as apoptosis in A549 human lung cancer cells. CBD treatment shows growth inhibition at concentrations above 20 μM, but FACS analysis shows low efficacy in terms of cell death. Microscopic observations suggest that multiple vesicles were detected in the cytoplasmic region of CBD-treated A549 cells. CBD treatment upregulates apoptosis-related proteins, such as p53, PARP, RIP1, RIP3, Atg12, and Beclin, indicating that CBD regulates several types of cell death. CBD treatment also induced E-cadherin, PPARγ, clathrin, β-adaptin, and Tsg101, also known to be cellular-differentiation inducers or vesicle-formation components. Treatment combining CBD with GW9662, a PPARγ inhibitor, reduced CBD-induced cytoplasmic vesicle formation. This indicates that PPARγ regulates the vesicle-formation mechanism. However, CBD-treated E-cad KO clones did not show this regulatory mechanism. These results elucidate the pharmacological and molecular networks associated with CBD in PPARγ-dependent vesicle formation and the induction of apoptosis.

25 January 2022 in Genes
Verified
Journal Article
Open access
PDF file
JRJae-min Ryu
Jae-min Ryu
HNHan-Heom Na
Han-Heom Na
YPYoon Jong Park
Yoon Jong Park
Jinsung ParkJinsung Park
Jinsung Park
Byung-Soo AhnByung-Soo Ahn
Byung-Soo Ahn
KKKeun-Cheol Kim
Keun-Cheol Kim
Sweet bee venom (sBV) contains various pharmacologically active components of bee venom (BV), but it is modified via the removal of the harmful substances found in BV. Thus, sBV has been used for pain relief in Oriental medicine but has only recently been applied for the treatment of various diseases. In this study, we examined the pharmacological effects and immunomodulatory functions of sBV in THP-1 monocytic leukemia cells. Growth inhibition and cell death were observed according to the concentration of sBV. However, the rapid collapse of cell cycle distribution was shown at 20 μg/mL sBV treatment, indicating that sBV led to cell death or acute cell rupture according to concentration. sBV administration activated Caspase-9, PARP1, RIPK1, and RIPK3, suggesting that the pharmacological actions of sBV were associated with induction of apoptosis and necroptosis. On the other hand, sBV or LPS administration increased cytokine expression, including IL-1β, and showed synergistic cell death in combinatory treatment conditions. Moreover, combinatory administration of sBV and LPS induced severe damage or death during egg development. This result implies that sBV exhibits both pharmacological and toxic effects depending on its concentration. Therefore, sBV might be a promising therapeutic approach, but optimal concentration should be considered before treatment.

30 June 2021 in Journal of Pharmacopuncture
Verified
Journal Article
Open access
PDF file
YPYoon Jong Park
Yoon Jong Park
JRJae-min Ryu
Jae-min Ryu
HNHan-Heom Na
Han-Heom Na
HJHyun Suk Jung
Hyun Suk Jung
BKBokhye Kim
Bokhye Kim
KKKeun-Cheol Kim
Keun-Cheol Kim
Yoon-Jong Park, Jae-Min Ryu, Han-Heom Na, Hyun-Suk Jung, Bokhye Kim, Jin-Sung Park, Byung-Soo Ahn, Keun-Cheol Kim. J Pharmacopuncture 2021;24:68-75. https://doi.org/10.3831/KPI.2021.24.2.68